Anti-COVID-19 Biologics – Using the BioPhorum Standard MAb Process to Estimate Required Manufacturing Infrastructure, Investment and Resulting Drug Cost



What would it take to rapidly manufacture 3 metric tonnes and then 10 metric tonnes of a mAb? Optimized product development procedures to speed up the transition of a discovered mAb into clinic and into commercialization have been discussed in an excellent article by Brian Kelley. What about subsequent commercial manufacturing capacity? According to Ecker and Seymour, 23 metric tons of approved biologics were produced in 2018, with 65% of that capacity controlled by 10 companies. Squeezing an extra 10% of the global capacity out of the network seems achievable, particularly if these top 10 companies are involved. We used Biosolve Process to estimate the current manufacturing capacity and timeframes for production of these products. Learn More